New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Pfizer Oncology announced today that data evaluating crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as well as data from Pfizer's renal cell carcinoma (RCC) portfolio on axitinib, an investigational compound, and SUTENT® (sunitinib malate) will be presented at the 2011 European Multidisciplinary Cancer Congress (EMCC) in Stockholm, Sweden, September 23 - 27, 2011.

"As SUTENT changed the treatment landscape for patients with advanced RCC, we have clinical evidence suggesting that crizotinib has the potential to change the treatment paradigm for patients with ALK-positive advanced NSCLC," said Dr. Mace Rothenberg, senior vice president of clinical development and medical affairs for Pfizer's Oncology Business Unit. "With data presentations at the meeting across compounds in lung and RCC, we are continuing to build on our experience and leadership in these disease areas."

Crizotinib Phase 2 Data

At the meeting, Pfizer will present updated data on the safety, efficacy and patient-reported outcomes (PROs) for crizotinib.

  • A global Phase 2 study including efficacy, safety, and patient-reported outcomes with crizotinib in patients with ALK-positive NSCLC (Poster Presentation, Abstract #9084, September 26)
  • Preliminary characterization of visual events reported by patients receiving crizotinib for the treatment of advanced ALK-positive NSCLC (Poster Presentation, Abstract #3030, September 26)

Pfizer Oncology: A Leader in RCC

As a leader in the treatment of advanced RCC, Pfizer Oncology is dedicated to offering multiple treatments and investigating new agents in different populations and stages of disease. We are committed to advancing the science of RCC through research into established and novel compounds, as well as the exploration of biomarkers to better personalize therapy and provide insights into treatment selection for patients with advanced kidney cancer.


As part of the ongoing evaluation of SUTENT, data being presented at the meeting include:

  • Prognostic factors for progression-free survival (PFS), overall survival (OS), and long-term OS with sunitinib in 1,059 patients, treated on clinical trials, with metastatic RCC (Oral Presentation, Abstract #1006, September 26).

SUTENT is approved for gastrointestinal stromal tumors (GIST) after disease progression on or intolerance to imatinib mesylate, as well as advanced RCC, and progressive, well-differentiated pancreatic neuroendocrine tumors (pancreatic NET) in patients with unresectable locally advanced or metastatic disease.


Data presentations for axitinib, an oral and selective inhibitor of VEGF 1, 2 and 3, receptors, include:

  • Association of single nucleotide polymorphisms (SNPs) in VEGF pathway genes with PFS and blood pressure in metastatic RCC in the Phase 3 trial of axitinib vs sorafenib (AXIS trial) (Oral presentation, Abstract #7103, September 24)
  • Time to deterioration (TTD) in patient-reported outcomes in Phase 3 AXIS trial of axitinib vs. sorafenib as second-line therapy for metastatic RCC (Poster Discussion, Abstract #3006, September 26)
  • A randomized Phase 2 study of axitinib dose titration in patients with advanced RCC: Preliminary pharmacokinetic and ambulatory blood pressure monitoring results (Poster Presentation, Abstract #7140, September 25)

Additionally, data on the following compounds will be presented: AROMASIN (exemestane) and neratinib.

Source: Pfizer


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Study shows efficacy of COVID-19 vaccine in people receiving cancer treatment